Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer’s Disease: A Randomized Controlled Trial—The OmegAD Study
Restricted accessResearch articleFirst published online September 28, 2021
Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer’s Disease: A Randomized Controlled Trial—The OmegAD Study
Studies have suggested a connection between a decrease in the levels of polyunsaturated fatty acids (PUFAs) and Alzheimer’s disease (AD). We aimed to assess the effect of supplementation with omega-3 fatty acids (n-3 FAs) on biomarkers analyzed in the cerebrospinal fluid (CSF) of patients diagnosed with AD.
Objective:
To investigate the effects of daily supplementation with 2.3 g of PUFAs in AD patients on the biomarkers in CSF described below. We also explored the possible correlation between these biomarkers and the performance in the cognitive test Mini-Mental State Examination (MMSE).
Methods:
Thirty-three patients diagnosed with AD were randomized to either treatment with a daily intake of 2.3 g of n-3 FAs (n = 18) or placebo (n = 15). CSF samples were collected at baseline and after six months of treatment, and the following biomarkers were analyzed: Aβ 38, Aβ 40, Aβ 42, t-tau, p-tau, neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), soluble IL-1 receptor type II (sIL-1RII), and IL-6.
Results:
There were no significant differences between the groups concerning the level of the different biomarkers in theCSF at baseline. Within the treatment group, there was a small but significant increase in both YKL-40 (p = 0.04) and NfL (p = 0.03), while the other CSF biomarkers remained stable.
Conclusion:
Supplementation with n-3 FAs had a statistically significant effect on NfL and YKL-40, resulting in an increaseof both biomarkers, indicating a possible increase of inflammatory response and axonal damage. This increase in biomarkers did not correlate with MMSE score.
FiestKM, RobertsJI, MaxwellCJ, HoganDB, SmithEE, FrolkisA, CohenA, KirkA, PearsonD, PringsheimT, Venegas-TorresA, JettéN (2016) The prevalence and incidence of dementia due to Alzheimer’s disease: A systematic review and meta-analysis. Can J Neurol Sci43, S51–S82.
2.
MotterR, Vigo-PelfreyC, KholodenkoD, BarbourR, Johnson-WoodK, GalaskoD, ChangL, MillerB, ClarkC, GreenR, OlsonD, SouthwickP, WolfertR, MunroeB, LieberburgI, SeubertP, SchenkD (1995) Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol38, 643–648.
3.
BouwmanFH, SchoonenboomNSM, VerweyNA, van ElkEJ, KokA, BlankensteinMA, ScheltensP, van der FlierWM (2009) CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging30, 1895–1901.
4.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.
5.
HesseC, RosengrenL, AndreasenN, DavidssonP, VandersticheleH, VanmechelenE, BlennowK (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett297, 187–190.
SelkoeDJ, HardyJ (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med8, 595–608.
8.
SkoogI, DavidssonP, AevarssonÓ, VandersticheleH, VanmechelenE, BlennowK (2003) Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds. Dement Geriatr Cogn Disord15, 169–176.
9.
WiltfangJ, EsselmannH, CupersP, NeumannM, KretzschmarH, BeyermannM, SchleuderD, JahnH, RütherE, KornhuberJ, AnnaertW, De StrooperB, SaftigP (2001) Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer’s disease and its generation in PS1 knockout cells. J Biol Chem276, 42645–42657.
10.
WiltfangJ, EsselmannH, BiblM, SmirnovA, OttoM, PaulS, SchmidtB, KlafkiHW, MalerM, DyrksT, BienertM, BeyermannM, RütherE, KornhuberJ (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J Neurochem81, 481–496.
KanaiM, MatsubaraE, IsoeK, UrakamiK, NakashimaK, AraiH, SasakiH, AbeK, IwatsuboT, KosakaT, WatanabeM, TomidokoroY, ShizukaM, MizushimaK, NakamuraT, IgetaY, IkedaY, AmariM, KawarabayashiT, IshiguroK, HarigayaY, WakabayashiK, OkamotoK, HiraiS, ShojiM (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer’s disease: A study in Japan. Ann Neurol44, 17–26.
13.
TamaokaA, SawamuraN, FukushimaT, ShojiS, MatsubaraE, ShojiM, HiraiS, FuriyaY, EndohR, MoriH (1997) Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Sci148, 41–45.
14.
GriffinT. WS, ShengJG, RobertsGW, MrakRE (1995) Interleukin-1 expression in different plaque types in Alzheimer’s disease. J Neuropathol Exp Neurol54, 276–281.
15.
DicksonDW, LeeSC, MattiaceLA, YenSC, BrosnanC (1993) Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia7, 75–83.
16.
BauerJ, StraussS, Schreiter-GasserU, GanterU, SchlegelP, WittI, YolkB, BergerM (1991) Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett285, 111–114.
17.
Del BoR, AngerettiN, LuccaE, De SimoniMG, ForloniG (1995) Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures. Neurosci Lett188, 70–74.
18.
AraujoDM, CotmanCW (1992) β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer’s disease. Brain Res569, 141–145.
19.
ToroVC, TehranianR, ZetterströmM, ErikssonG, LangelU, BartfaiT, IverfeldtK (2001) Increased gene expression of interleukin-1α and interleukin-6 in rat primary glial cells induced by β-amyloid fragment. J Mol Neurosci17, 341–350.
20.
HamaT, KushimaY, MiyamotoM, KubotaM, TakeiN, HatanakaH (1991) Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience40, 445–452.
21.
BrosseronF, KrauthausenM, KummerM, HenekaMT (2014) Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: A comparative overview. Mol Neurobiol50, 534–544.
22.
ColottaF, ReF, MuzioM, BertiniR, PolentaruttiN, SironiM, GiriJG, DowerSK, SimsJE, MantovaniA (1993) Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science261, 472–475.
23.
ReF, SironiM, MuzioM, MatteucciC, IntronaM, OrlandoS, Penton-RolG, DowerSK, SimsJE, ColottaF, MantovaniA (1996) Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: A surface ‘Receptor’ with anti-interleukin-1 function. J Exp Med183, 1841–1850.
24.
GarlindA, BraunerA, HöjebergB, BasunH, SchultzbergM (1999) Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer’s disease patients. Brain Res826, 112–116.
25.
HolmgrenS, HjorthE, SchultzbergM, LärksäterM, FrenkelD, Tysen-BäckströmAC, AarslandD, Freund-LeviY (2014) Neuropsychiatric symptoms in dementia-A role for neuroinflammation?Brain Res Bull108, 88–93.
26.
BjerkeM, ZetterbergH, EdmanÅ, BlennowK, WallinA, AndreassonU (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis27, 665–676.
27.
KesterMI, TeunissenCE, SutphenC, HerriesEM, LadensonJH, XiongC, ScheltensP, Van Der FlierWM, MorrisJC, HoltzmanDM, FaganAM (2015) Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther7, 59.
JohanssonP, AlmqvistEG, JohanssonJO, MattssonN, AndreassonU, HanssonO, WallinA, BlennowK, ZetterbergH, SvenssonJ (2013) Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer’s disease. PLoS One8, e81989.
30.
KawakatsuS, MorinobuS, ShinoharaM, TotsukaS, KobashiK (1990) Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer’s disease. Biol Psychiatry28, 387–400.
31.
AtackJR, MayC, KayeJA, KayAD, RapoportSI (1988) Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. Ann Neurol23, 161–167.
32.
MesulamM -M, Asuncion MoránM (1987) Cholinesterases within neurofibrillary tangles related to age and Alzheimer’s disease. Ann Neurol22, 223–228.
33.
PerryEK, PerryRH, BlessedG, TomlinsonBE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol4, 273–277.
34.
KuhlDE, KoeppeRA, SnyderSE, MinoshimaS, FreyKA, KilbournMR (2006) In vivo butyrylcholinesterase activity is not increased in Alzheimer’s disease synapses. Ann Neurol59, 13–20.
35.
AppleyardME, McDonaldB (1992) Acetyicholinesterase and butyryicholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry55, 1074–1078.
36.
ConquerJA, TierneyMC, ZecevicJ, BettgerWJ, FisherRH (2000) Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids35, 1305–1312.
37.
SöderbergM, EdlundC, KristenssonK, DallnerG (1991) Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids26, 421–425.
38.
LukiwWJ, CuiJG, MarcheselliVL, BodkerM, BotkjaerA, GotlingerK, SerhanCN, BazanNG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest115, 2774–2783.
39.
LimGP, CalonF, MoriharaT, YangF, TeterB, UbedaO, SalemN, FrautschySA, ColeGM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci25, 3032–3040.
40.
GreenKN, Martinez-CoriaH, KhashwjiH, HallEB, Yurko-MauroKA, EllisL, LaFerlaFM (2007) Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci27, 4385–4395.
KawashimaA, HaradaT, ImadaK, YanoT, MizuguchiK (2008) Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1β-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostaglandins Leukot Essent Fat Acids79, 59–65.
43.
HjorthE, ZhuM, ToroVC, VedinI, PalmbladJ, CederholmT, Freund-LeviY, Faxen-IrvingG, WahlundLO, BasunH, EriksdotterM, SchultzbergM (2013) Omega-3 fatty acids enhance phagocytosis of Alzheimer’s disease-related amyloid-β42 by human microglia and decrease inflammatory markers. J Alzheimers Dis35, 697–713.
44.
Freund-LeviY, HjorthE, LindbergC, CederholmT, Faxen-IrvingG, VedinI, PalmbladJ, WahlundLO, SchultzbergM, BasunH, Eriksdotter JönhagenM (2009) Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer’s disease: The OmegAd study. Dement Geriatr Cogn Disord27, 481–490.
45.
Freund LeviY, VedinI, CederholmT, BasunH, Faxén IrvingG, EriksdotterM, HjorthE, SchultzbergM, VessbyB, WahlundLO, SalemN, PalmbladJ (2014) Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer’s disease: The OmegAD study. J Intern Med275, 428–436.
46.
FolsteinMF, FolsteinSE, McHughPR (1975) ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
47.
Freund-LeviY, Eriksdotter-JönhagenM, CederholmT, BasunH, Faxén-IrvingG, GarlindA, VedinI, VessbyB, WahlundLO, PalmbladJ (2006) ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study - A randomized double-blind trial. Arch Neurol63, 1402–1408.
48.
ParnettiL, ChiasseriniD, AndreassonU, OhlsonM, HülsC, ZetterbergH, MinthonL, WallinAK, AndreasenN, TalesaVN, BlennowK (2011) Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease. Acta Neurol Scand124, 122–129.
49.
SalbergS, YamakawaG, ChristensenJ, KolbB, MychasiukR (2017) Assessment of a nutritional supplement containing resveratrol, prebiotic fiber, and omega-3 fatty acids for the prevention and treatment of mild traumatic brain injury in rats. Neuroscience365, 146–157.
50.
OliverJM, JonesMT, KirkKM, GableDA, RepshasJT, JohnsonTA, AndréassonU, NorgrenN, BlennowK, ZetterbergH (2016) Effect of docosahexaenoic acid on a biomarker of head trauma in American Football. Med Sci Sports Exerc48, 974–982.
OlssonB, PorteliusE, CullenNC, SandeliusÅ, ZetterbergH, AndreassonU, HöglundK, IrwinDJ, GrossmanM, WeintraubD, Chen-PlotkinA, WolkD, McCluskeyL, ElmanL, ShawLM, ToledoJB, McBrideJ, Hernandez-ConP, LeeVMY, TrojanowskiJQ, BlennowK (2019) Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol76, 318–325.
53.
ZetterbergH, SkillbäckT, MattssonN, TrojanowskiJQ, PorteliusE, ShawLM, WeinerMW, BlennowK (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol73, 60–67.
54.
JanelidzeS, MattssonN, StomrudE, LindbergO, PalmqvistS, ZetterbergH, BlennowK, HanssonO (2018) CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology91, e867–e877.
55.
Gopuran DevassyJ, LengS, GabbsM, MonirujjamanM, AukemaHM (2016) Omega-3 polyunsaturated fatty acids and oxylipins in neuroinflammation and management of Alzheimer disease. Adv Nutr7, 905–916.
56.
BrambillaR (2019) The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol137, 757–783.
57.
WrightCI, GeulaC, MesulamMM (1993) Neuroglial cholinesterases in the normal brain and in Alzheimer’s disease: Relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol34, 373–384.
58.
DasUN (2007) Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation.RA. Med Sci Monit13, 214–21.
